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Abstract
The bovine papillomavirus type 1 (BPV-1) genome has been shown to contain a small open-reading frame designated E5B (nucleotides
4013–4167) which is predicted to encode a hydrophobic, 52 amino acid protein. In order to detect and characterize the E5B protein, an 18
nucleotide sequence encoding a 6 amino acid epitope was added to the 3 end of the E5B open-reading frame which was then expressed
in COS-1 cells using a SV40 vector. Immunoprecipitation, immunofluorescence, and cell fractionation studies identified the E5B protein as
a 4-kDa protein and localized it primarily to membranes of the endoplasmic reticulum and nucleus. Unlike the E5A protein of BPV-1, E5B
did not form dimers (despite containing a cysteine residue) or form complexes with growth factor receptors such as the PDGF receptor or
erb B-2 receptor. Interestingly, the E5B protein formed physical complexes with the hydrophobic E5A oncoprotein, apparently via
transmembrane interactions. Additionally, expression of E5B inhibited the transforming capability of BPV-1 E5A. These observations
suggest that the expression of this viral protein may play a significant role in BPV/host cell interactions.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Papillomaviruses (PVs) are the etiological agents of be-
nign epithelial tumors in vertebrates (Broker et al., 1986;
Sundberg et al., 1984) and, in humans, play a critical role in
the development of cervical dysplasia and carcinoma (Giss-
mann et al., 1984; zur Hausen and Schneider, 1987). Bovine
papillomavirus type 1 (BPV-1) is a prototype PV which has
been used extensively to genetically dissect the viral genes
which induce in vitro cellular transformation (DiMaio et al.,
1986; Leptak et al., 1991; Schlegel and Wade-Glass, 1987).
Sequence analysis indicates that the BPV-1 genome con-
tains eight early and two late open-reading frames (ORFs)
(Chen et al., 1982). The early ORFs are expressed via a
complex splicing mechanism and encode several proteins
which regulate viral DNA replication, RNA transcription,
and cell transformation (Chen et al., 1982). The E5 ORF
encodes a 44 amino acid, hydrophobic protein which is
responsible for 95–100% of the in vitro-transforming activ-
ity of BPV-1 DNA (Burkhardt et al., 1987; Horwitz et al.,
1988, 1989; Lowy et al., 1980; Schlegel et al., 1986; Settle-
man et al., 1989). E5, which is membrane-embedded and
localizes predominantly to the Golgi apparatus with its
carboxyl terminus oriented intraluminally (Burkhardt et al.,
1989), cooperates with growth factor receptors (platelet-
derived growth factor [PDGF] receptor, epidermal growth
factor receptor, and colony-stimulating factor 1 receptor) to
induce transformation of NIH 3T3 cells (Martin et al., 1989;
Petti et al., 1991). Additional studies indicate that the E5-
mediated transformation of fibroblasts involves the activa-
tion of the endogenous PDGF receptor (Petti et al., 1991;
Petti and DiMaio, 1992) and that E5 can physically associ-
ate with this receptor complex. Interestingly, E5 appears to
be in a ternary complex with the PDGF-R as well as the 16K
protein of the vacuolar H-ATPase (Goldstein et al., 1991,
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1992; Petti and DiMaio, 1992). The formation of this com-
plex depends upon interactions of alpha-helical, transmem-
brane domains (Goldstein et al., 1992; Petti, et al., 1991;
Petti and DiMaio, 1992).
The existence of an additional BPV-1 early ORF (E5B)
has been demonstrated which has the potential to encode a
52 amino acid hydrophobic protein that is rich in leucine
residues and appears similar to some of the human papillo-
mavirus (HPV) E5 proteins in predicted structure and amino
acid composition (O’Banion et al., 1993). The presence and
presumably the expression of the E5B gene induces the
accumulation of several resident ER proteins in transformed
murine fibroblasts (C127) and a point mutation in its initi-
ation codon eliminates this activity while maintaining cel-
lular transformation by the intact E5A (originally E5) ORF
(O’Banion et al., 1993). To determine whether the BPV-1
early region can synthesize an E5B protein and to evaluate
its biochemical properties, we tagged the E5B ORF with a
synthetic epitope to allow its immunologic detection.
Results
Construction of vectors for the transient expression of the
epitope-tagged E5B ORF
Since antibodies were unavailable for the native E5B
protein, it was necessary to append a synthetic epitope
(AU1) on the carboxyl terminus of E5B to allow for its
immunologic detection and biochemical characterization.
This six amino acid epitope (DTYRYI) has been used suc-
cessfully on the hydrophobic E5A protein without affecting
protein function (Goldstein et al., 1992; Sparkowski et al.,
1994). The AU1-tagged E5B gene was cloned into two
different expression vectors. The first vector, pSVL, was
used for transient transfection experiments and utilized the
SV40 origin of replication and late promoter for inducing
high-level expression of the tagged E5B protein in COS-1
cells. The recombinant pSVL clone containing the tagged
E5B ORF was designated pTW2 (Fig. 1A).
The second vector, pJS55 (Sparkowski et al., 1994), was
used to construct pTW69 (Fig. 1B), which was subsequently
utilized for transient transfection and used the SV40 origin
of replication and early promoter for inducing high-level
expression of the tagged E5B protein in COS-1 cells.
Tagged E5B expression from pTW69 was additionally reg-
ulated by native BPV-1 transcriptional control mechanisms
that operate in this region of the BPV-1 genome (E2–
E5AB). An epitopeless E5B expression vector (pTW12)
was also constructed utilizing the pJS55 backbone. Plas-
mids pTW2, pTW12, and pTW69 contain the E5B ORF
while only pTW2 and pTW69 contain the AU1-epitope
DNA sequence at their 3 ends as confirmed by sequence
analysis (data not shown).
Detection of E5B protein in transiently transfected cells
In order to identify the E5B protein, COS-1 cells were
transfected with plasmid pTW2 and labeled metabolically
with [35S]-methionine-cysteine 48 h posttransfection. The
cells were then extracted and immunoprecipitated with
monoclonal antibody (MAb) AU1 as described under Ma-
terials and methods. As indicated in Fig. 2, COS-1 cells
transfected with pTW2 expressed a new 4 kDa (predicted
Fig. 1. Expression plasmids for epitope-tagged BPV-1 E5B protein. (A)
Plasmid pSVL (containing the pBR322 ori, SV40 ori, SV40 late promoter,
VP1 intron, and the SV40 late polyadenylation site) was cleaved at the
polylinker with XhoI/BamHI restriction enzymes to allow insertion of the
isolated AU1-tagged E5B ORF (pTW2). (B) Plasmid pTW69 is a deriva-
tive of C88 (see Materials and methods) which contains the subgenomic
transforming fragment (E2-E5AB) of BPV-1. Plasmid pJS55 was cleaved
with XhoI/BglII to allow insertion of the XhoI/BamHI fragment from
pTW3. A fragment from C88 (cut with BamHI/SpeI), spanning the entire
E2 ORF and the first 11 codons of the E5A ORF, was ligated into
BamHI/SpeI-cut pTW68. This final expression construct, pTW69, contains
the entire BPV-1-transforming region with the addition of the AU1 coding
sequence at the 3 end of E5B.
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molecular weight is 6.8 kDa) polypeptide, E5B (lane 2),
which was absent from COS-1 cells transfected with the
control vector (lane 1).
The E5B gene encodes a cysteine residue at amino acid
position 15 that could potentially facilitate homodimeriza-
tion via disulfide bonds. The E5A protein, which contains a
Cys-X-Cys sequence near its carboxyl terminus, has already
been shown capable of forming homodimers and higher
order oligomers (Goldstein et al., 1992; Petti and DiMaio,
1992). To evaluate whether E5B could also form dimers,
immunoprecipitates of the E5B protein were separated on
acrylamide gels in the absence of -mercaptoethanol (Fig.
2, lane 3). No change was observed in the electrophoretic
mobility of E5B in the absence of the reducing agent,
indicating that the BPV-1 E5B protein does not form dimers
or oligomers through disulfide linkages.
An E5B protein is expressed in cells transiently
transfected by the BPV-1 subgenomic transforming
fragment
While we could clearly detect the E5B protein in COS-1
cells when expressed by a strong SV40 promoter, it was
critical to demonstrate that this protein was also expressed
when native transcriptional controls (native promoters and
splicing signals) were intact. To achieve the above goal, the
construct pTW69 (Fig. 1B), containing the subgenomic
transforming fragment of BPV-1 capable of expressing the
E2, E3, E4, E5A, and E5B genes was altered to express an
AU1-tagged E5B ORF for detection purposes. At 48 h
posttransfection, cells were metabolically labeled with
[35S]methionine-cysteine and immunoprecipitated with
MAb AU1. Results from a representative experiment are
illustrated in Fig. 3. COS-1 cells transfected with pTW69
expressed an E5B protein (lane 5) which comigrated with
the E5B protein expressed in COS-1 cells transfected with
pTW2 (lane 3). This protein was absent in vector-trans-
fected COS-1 cells (lane 2). The cloning process, impor-
tantly, did not effect the expression of the E5A protein
(lanes 4 and 5). Previous experiments (Goldstein et al.,
1992), as well as our own observations (data not shown),
demonstrated that AU1 does not precipitate wild-type E5A.
The E5B protein localizes to endoplasmic reticulum and
nuclear membranes
Immunofluorescence (IF) microscopy was used to deter-
mine the intracellular localization of the BPV-1 E5B pro-
tein. COS-1 cells grown on glass coverslips were trans-
fected with pTW2 (expressing E5B), pTA6 (expressing
E5A), and control vector and then fixed in 3.7% formalde-
hyde 48 h posttransfection. Cells were then permeabilized
with 0.1% saponin and blocked with 10% normal goat
serum (NGS) and proteins were localized with MAb AU1
(for E5B) or an anti-E5A polyclonal antibody. A rhodam-
ine-conjugated goat anti-mouse or goat anti-rabbit immu-
noglobulin G (IgG) secondary antibody was used to detect
the primary antibodies. The E5B protein exhibited pro-
nounced, reticular, cytoplasmic staining, characteristic of
the endoplasmic reticulum (Fig. 4A). This staining pattern is
highly reminiscent of the pattern identified using ER reten-
tion mutants of E5A (Sparkowski et al., 1995). To a lesser
degree, E5B was also noted in nuclear membranes (Fig. 4A)
and perinuclear membranes characteristic of the Golgi ap-
paratus. As demonstrated previously (Burkhardt et al.,
1989; Goldstein and Schlegel, 1990), E5A was localized
predominantly in the Golgi apparatus (Fig. 4B), although
some localization was also observed in the ER and nuclear
membranes. No staining for E5B was observed in cells
transfected with the control vector alone (Fig. 4C) or in
E5A- and E5B-transfected cells reacted with irrelevant pri-
mary antibodies, respectively (data not shown).
BPV-1 E5B associates with cellular membrane fractions
In order to confirm biochemically the microscopic local-
ization of E5B in cell membranes, E5B-expressing cells
were fractionated by hypotonic lysis and differential cen-
trifugation and the fractions assayed for E5B. COS-1 cells
were transfected with pTW2 or pSVL and metabolically
labeled with [35S]-methionine-cysteine 48 h after transfec-
tion. Washed cells were treated with a hypotonic citrate
solution and disrupted as described previously (Burkhardt et
al., 1987). The cell homogenates were separated by differ-
ential centrifugation into nuclear, membrane, and cytoplas-
Fig. 2. Expression of the E5B protein in COS-1 cells. COS-1 cells were
transfected with plasmid pTW2 (10 g). Forty eight hours posttransfection,
the cells were labeled with [35S]-methionine-cysteine for 4 h, extracted,
and immunoprecipitated with MAb AU1, and separated by SDS-PAGE.
The E5B protein migrates as a 4-kDa protein (arrow). Samples were run
with () and without () the reducing agent, -mercaptoethanol (-mer).
COS-1 cells transfected with vector (10 g) alone were also immunopre-
cipitated with MAb AU1 as a control (lane 1). Molecular sizes (in kilo-
daltons) are indicated.
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mic fractions that were then immunoprecipitated with MAb
AU1 and resolved by sodium dodecyl sulfate-polyacrylam-
ide gel electrophoresis (SDS-PAGE) (Fig. 5). The mem-
brane fraction contained the majority of the E5B protein
while a lesser amount was located in the nuclear fraction.
Only a trace of E5B was detected in the cytoplasmic frac-
tion (most likely as a result of cytoplasmic fraction contam-
ination by membrane components). No E5B protein was
detected from any fraction of COS-1 cells transfected with
the vector alone. The fractionation studies, therefore, sup-
port the immunofluorescence studies that localized E5B
mainly in ER membranes and to a lesser extent in nuclear
membranes.
BPV-1 E5B associates with BPV-1 E5A in cotransfected
COS-1 cells
Lanes 4 and 5 of Fig. 3 suggested that there maybe an
interaction between E5A and E5B. Since both E5A and E5B
are hydrophobic proteins that are present to some degree in
the same cellular membranes (such as ER membranes), we
evaluated whether they might form a physical complex in
the cell. Construct pTW2 (E5B with the AU1 epitope) was
cotransfected into COS-1 cells with pTA6 (E5A). After
metabolically labeling the transfected COS-1 cells with
[35S]-methionine-cysteine, cell extracts were either immu-
noprecipitated with AU1 (which recognizes the E5B pro-
tein) or with an anti-E5A polyclonal antibody (which rec-
ognizes the 7-kDa E5A protein). The results demonstrated
that E5A was associated with E5B in an immunoprecipitate
complex. This association was evident when using an anti-
body specific for either E5A or E5B (Fig. 6A, lanes 7 and
8). The anti-E5A and AU1 antibodies showed specificity for
both E5A and tagged E5B, respectively (Fig. 6A, lanes
3–6), and did not detect proteins of equivalent molecular
weight in mock-transfected cell lysates (Fig. 6A, lanes 1 and
2). The apparent lesser expression of E5B compared to E5A
may be related to the number of methionine and cysteine
residues present in each protein. Following cellular process-
ing, E5A would contain three metabolically labeled residues
(one methionine and two cysteines) compared with two
metabolically labeled residues in E5B (one methionine and
one cysteine).
It is also important to note that in other immunoprecipi-
tation experiments (Fig. 6B) using lysates from E5A/wild-
type E5B cotransfected COS-1 cells, immunoprecipitating
with an anti-E5A antibody alone, it was possible to identify
an association between the E5A protein and the native E5B
protein (Fig. 6B, lane 2). This association demonstrates that
the E5A/E5B interaction described previously is not depen-
dent on the AU1 epitope appended to the E5B carboxy
terminus. The lack of an antibody to the native E5B protein
does not allow the reverse experiment to be examined.
Of greater interest is the observation that E5A and E5B
associate in COS-1 cells containing a subgenomic trans-
forming fragment of BPV-1 (Fig. 3). When gels containing
Fig. 3. Expression of the E5B protein in COS-1 cells transiently transfected by a subgenomic fragment of BPV-1. Plasmid pTW69 contains a subgenomic
fragment of BPV-1 that encodes the region spanning the E2 thru E5AB genes. Transfected COS-1 cells were labeled with [35S]methionine-cysteine, extracted,
and immunoprecipitated with either MAb AU1 (for E5B) or an anti-E5A antibody. Lysates from two 15-cm plates were combined for each immunopre-
cipitation. The E5B protein (lane 5) expressed by pTW69 migrated as a 4-kDa band (arrow) in contrast to E5A (lane 4), which migrated as a 7-kDa protein
(arrow). An E5B protein marker was generated in COS-1 cells transfected with pTW2 (lane 3). Labeled COS-1 cells transfected with vector DNA and
immunoprecipitated with anti-E5A antibody and MAb AU1 were used as negative controls (lanes 1 and 2, respectively). Molecular sizes (in kilodaltons) are
indicated. A 3 overexposure of gel lanes 4 and 5 is enlarged at the right.
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precipitated lysates from COS-1 cells transfected with
pTW69 (E2-E5AB) were exposed to film for an extended
period (3, lanes 4 and 5), it was observed that the E5A
protein coprecipitates the E5B protein, suggesting that the
observed association may occur during natural infection.
BPV-1 E5B does not detectably associate with the PDGF
receptor, erb B-2 receptor, or major histocompatibility com-
plex I (MHC I) proteins. To determine the specificity of the
interaction of the BPV-1 E5B protein with the BPV-1 E5A
protein and also to identify E5B-associated proteins, we
cotransfected the plasmid DNAs of E5B and other integral
membrane proteins. Interaction of the E5A protein with the
PDGF receptor has already been established (Goldstein et
al., 1992; Petti and DiMaio, 1992). To evaluate whether
E5B can also form such complexes with growth factor
receptors, we cotransfected COS-1 cells with E5B (pTW2)
and either the human PDGF receptor (pSVPR) or human erb
B-2 receptor (pSVerb B-2). After metabolically labeling
with a mixture of [35S]-methionine-cysteine, cells were ex-
tracted and immunoprecipitated with AU1 and anti-receptor
MAbs to determine the presence of protein complexes.
Immunoprecipitates showed no association of the BPV-1
E5B protein with either the PDGF receptor or the erb B-2
receptor in COS-1 cells (data not shown).
We also examined whether E5B could associate with
another integral membrane protein complex, MHC I. E5A
does not associate with this protein complex (Goldstein et
al., 1992). Although COS-1 cells endogenously expressed
large amounts of both the alpha chain and 2-microglobulin
components of MHC I, no association was demonstrated
using either antibodies against E5B or MHC I (data not
shown).
Inhibition of E5A-transforming ability by E5B
The demonstration that tagged E5B bound to E5A was
compatible with the finding that coexpression of E5B and
E5A in murine fibroblasts inhibited the transforming activ-
ity of E5A (Table 1). In evaluating this, subconfluent C127
cells were cotransfected with 9 g of E5B and 1 g of E5A.
Upon reaching confluency, cells were transferred to 162-
cm2 flasks and allowed to form foci. The number of foci
formed after 2–3 weeks were compared with the number of
foci in flasks transfected with E5B or E5A alone. The table
illustrates that the inhibitory effect was between 52 and 62%
and probably reflected the observation that E5B is not as
abundantly expressed as E5A and that E5A and E5B are
present predominantly in different cell membrane compart-
ments.
Discussion
In this study we have expressed a tagged E5B protein of
BPV-1 and shown that it is present primarily in ER mem-
branes and that it associates with the E5A protein.
Epitope addition
Currently there are no antibodies against the native E5B
protein. However, previous studies have determined that
epitope addition can allow identification of proteins when
no native protein-specific antibody is available (Field et al.,
1988; Goldstein et al., 1991). In this study, the use of the
AU1 epitope on the carboxyl terminus of E5B and the
efficient high-level expression achieved by SV40 expres-
sion vectors have made it possible to express and charac-
terize this protein. The small size of the antigenic epitope
and the availability of a highly reactive monoclonal anti-
body made it a desirable choice for detecting the E5B
protein. Previous studies with the BPV-1 E5A protein
(Goldstein et al., 1992; Sparkowski et al., 1994) have shown
the efficacy of the epitope in immunoprecipitation assays
and demonstrated that it does not interfere with the local-
Fig. 4. Intracellular localization of E5B by immunofluorescence micros-
copy. COS-1 cells were grown on glass coverslips, transfected with 10 g
pTW2 (E5B), pTA6 (E5A), or vector and fixed with formaldehyde 48 h
after transfection. The cells were reacted with AU1 or anti-E5A and
rhodamine-conjugated secondary antibodies as described under Materials
and methods and examined with an UV epifluorescence microscope. (A)
Localization of E5B with AU1. (B) Localization of E5A with anti-E5A
antibody. (C) Vector-transfected cells stained with AU1.
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ization or biological activity of E5A. A similar study has
also been performed with AU1-tagged 16K protein (Gold-
stein et al., 1992). Since little is known about the function
(and therefore the functional domains) of E5B, the epitope
was added to the carboxyl terminus since this location
should facilitate its exposure to antibody, minimize its po-
tential interference with protein function, and reduce the
number of genetic manipulations necessary for epitope ad-
dition.
The presence of the E5B protein in COS-1 cells trans-
fected with the E2-E5AB fragment of BPV-1 and the ob-
servation that E5A and E5B can associate in these cell lines
suggest that E5B may have a functional role during in vivo
viral infections. While genetic analysis has defined the E5B
ORF as encoding a protein which is capable of inducing
glycosylation modifications of endogenous ER proteins
such as grp100 (O’Banion et al., 1993), it is not clear at the
present time how these protein-processing modifications
might contribute to the viral life cycle. However, it should
now be possible to evaluate the ability of E5B to indepen-
dently induce these alterations and to molecularly dissect
the functional domains of E5B.
Biochemical properties of the BPV-1 E5B protein
The BPV-1 E5B protein was first detected in COS-1 cells
as a 4-kDa polypeptide. Though a predicted size of 6.8 kDa
was expected, it is unlikely that the AU1 epitope alters E5B
mobility since it has not been observed to alter the mobility
of other tagged hydrophobic proteins (unpublished results;
Goldstein et al., 1992; Sparkowski et al., 1994). The elim-
ination of reducing agent also did not affect the mobility of
E5B, indicating that the sole cysteine did not participate in
disulfide bond formation.
BPV-1 E5B was shown to bind to the E5A protein and it
is believed that the hydrophobic domains of these respective
proteins mediate this interaction. The association of E5A
with wild-type E5B suggests that the protein/protein inter-
action is not due to the AU1 epitope. Definition of the
precise interacting domains of these proteins will require
mutagenesis of the E5B protein and the utilization of avail-
able E5A mutants. Interestingly, E5B was unable to inde-
pendently interact with the PDGF receptor that is one of the
cellular targets for E5A. However, it is possible that E5B
might exist in a complex with the PDGF receptor if E5A
were present. Similar to its lack of direct interaction with
PDGF receptor, E5B did not bind to the erb B-2 receptor or
the integral membrane complex MHC I, indicating that
there is specificity for which transmembrane protein E5B
will bind.
The BPV-1 E5B protein is a membrane-associated pro-
tein that is distributed in cellular membranes, specifically
the ER and nuclear membranes. This membrane localization
somewhat overlaps that of E5A; however, E5A predomi-
nantly resides in membranes of the Golgi apparatus. The ER
membrane localization of the two proteins provides an op-
portunity for them to form physical complexes, although
they may have only a limited time to interact before E5A
translocates to the Golgi apparatus. In light of their local-
ization differences, a direct interaction of E5A and E5B can
additionally be inferred based on the ability of E5B to
inhibit E5A-mediated cellular transformation. Additional
evidence that coexpression of E5A-binding proteins can
inhibit E5A-mediated transformation has been demon-
strated by coexpressing the cellular 16K protein (Andresson
et al., 1995). It is possible that E5B may regulate the amount
of E5A protein that is able to bind other cellular proteins
(such as PDGF receptor or 16K) and additional experiments
Fig. 5. Intracellular localization of E5B by cell fractionation. COS-1 cells transfected with vector or pTW2 (10 g each) were analyzed 48 h posttransfection
for the presence of the E5B protein. Labeled cells were washed and disrupted before differential centrifugation to separate the indicated cellular components.
The nuclear (nuc), membrane (mem), and cytoplasmic (cyto) fractions were derived from two 10-cm plates, immunoprecipitated with MAb AU1 and
separated by SDS-PAGE. The E5B marker is from a pTW2-transfected COS-1 cell lysate. Molecular sizes (in kilodaltons) are indicated.
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will be necessary to investigate this possibility. The pre-
dominant ER localization of E5B also provides an oppor-
tunity for it to modify the glycosylation of resident ER
proteins as previously described (O’Banion et al., 1993). In
the future, it will be important to generate antibodies spe-
cific for the native form of E5B to permit verification of the
localization of native E5B in cultured fibroblasts as well as
allow the detection of E5B in bovine fibropapillomas.
Materials and methods
Cell culture
COS-1 and NIH 3T3 cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM [Life Technologies,
Grand Island, NY]) supplemented with 10% fetal bovine
serum.
Plasmid constructions
Plasmids pTW2 (Fig. 1A) and pTW3 (not shown) are
derivatives of pSVL (Amersham/Pharmacia Biotech Inc.,
Piscataway, NJ), which contains the SV40 late promoter
and polyadenylation sequences. Plasmid pTW2 expresses
the E5B ORF with additional coding for the AU1 epitope
(DTYRYI) appended to the 3 end of the gene. Plasmid
pTW3 contains the entire E5 coding region (E5A–E5B)
with AU1 also on the 3 end of the E5B ORF. These inserts
were generated through the use of polymerase chain reac-
tion (PCR). The insert for pTW2 was generated with the 5
Fig. 6. BPV-1 E5B associates with BPV-1 E5A. COS-1 cells were cotransfected with 5 g pTW2 (AU1-tagged E5B) or 5 g pTW12 (nontagged E5B) and
5 g of pTA6 (E5A) and labeled 48 h after transfection with [35S]methionine-cysteine. (A) Samples were immunoprecipitated with either AU1 or an anti-E5A
antibody and then analyzed by SDS-PAGE. Lysates from COS-1 cells transfected with vector (10 g) and immunoprecipitated with AU1 or the anti-E5A
antibody (lanes 1 and 2). (B) Lane 1, E5A mobility. Lane 2, cell lysates from E5A and E5B (nontagged) cotransfected COS-1 cells immunoprecipitated with
anti-E5A antibody. Molecular sizes (in kilodaltons) are indicated.
Table 1
Inhibition of E5A-transforming ability by E5B in C127 cells
Group DNA transfected (g) Number of focia
vector E5A E5B Trial 1 Trial 2
() Control 10 — — 0 0
E5A 9 1 — 62 52
E5B — — 10 0 1
E5A/E5B — 1 9 23 25
a Foci per 162-cm2 flask were allowed to grow for 3 weeks posttrans-
fection (Sparkowski et al., 1994). Foci were counted and numbers pre-
sented represent averages/group according to the number of replicate
flasks/group/trial: control, 1; E5A, 3; E5B, 2; E5A/E5B, 3.
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oligonucleotide TW 5: 5-TTACATCTCGAGGCCAC-
CATGCCTTTACATCAC-3 and the 3 oligonucleotide
TW 6 : 5-ATAGCTGGATCCTTATATATAGCGATAG-
GTGTCAACCATATAAAA-3. The insert for pTW3 was
synthesized with the 5 oligonucleotide ON 1: 5-TTA-
CATCTCGAGGCCACCATGCCAAATCTA-3 and the 3
oligonucleotide TW 6. Both 5 oligonucleotides contain
sequences for a XhoI restriction site followed by a Kozak
translational sequence (Kozak, 1987) immediately upstream
of the translational start site. The 3 oligonucleotide con-
tains the sequence for a BamHI restriction site immediately
downstream of the translational stop codon.
Plasmid pTW69 (Fig. 1B) is a modified version of the
C88 construct (Yang et al., 1985). First, the E5AB region
was excised from pTW3 by XhoI/BamHI digestion then
ligated into the XhoI/BglII sites of pJS55 (Sparkowski et al.,
1994). The resulting construct (pTW68) was then digested
with BamHI/SpeI to which was ligated the BamHI/SpeI
fragment (E2 thru 5 end of E5A) from C88. The resulting
plasmid, pTW69, then contained the E2-E5AB region of
BPV-1, where the E5B gene now encoded the AU1 epitope.
Plasmid pTW12 utilizes the pJS55 cassette to express the
unaltered, i.e., wild-type, BPV-1 E5B ORF. Oligonucleo-
tide TW 5 and oligonucleotide TW 22 (identical to TW 6
but lacking the AU1 epitope nucleotide sequence) were
used to generate the nontagged E5B gene.
The plasmids pTA6, pSVPR (Goldstein et al., 1992), and
pSVerb B-2 (Conrad et al., 1993) have been described
previously.
DNA transfections
Transient transfection of COS-1 cells with DNA con-
structs was achieved by a modified calcium phosphate
method (Graham and van der Eb, 1973). Briefly, cells were
plated at approximately 40% confluency in 10-cm dishes. A
total of 10 g DNA consisting of 5–10 g of test plasmid
and the remainder carrier DNA (pSVL or pJS55) was added
to 500 l Hepes (N-2-hydroxyethylpiperazine-N-2-ethane-
sulfonic acid)-buffered saline (HBS), pH 7.05. Fifty micro-
liters of 1.25 M CaCl2 solution was slowly added with
mixing and allowed to incubate at room temperature for 30
min. The mixture was then added to COS-1 cells in 5 ml
fresh DMEM and incubated at 37°C. After 16–18 h, the
cells were washed once with phosphate-buffered saline
(PBS) and then shocked for 60 s with 15% glycerol in 1X
HBS. Cells were immediately washed again three times and
further incubated at 37°C in 10 ml DMEM plus 10% fetal
bovine serum 48 h prior to analysis.
Focus formation assay
The assay was performed essentially as described previ-
ously (Sparkowski et al., 1994). Briefly, C127 cells were
transfected as described above. After transfection, cells
were allowed to grow to confluency. Each 10-cm plate was
then trypsinized, transferred to a 162-cm2 flask, and refed
with fresh DMEM every third day for 2 to 3 weeks. Foci
were quantitated after staining with 1% methylene blue in
100% ethanol for 15 to 30 min and rinsed with water.
Immunofluorescence assay
Subconfluent COS-1 cells grown on 18-mm glass cov-
erslips were transfected with 10 g of pTW2, pTA6, or
pSVL as described above. Forty-eight hours after glycerol
shock, the cells were washed twice with PBS and fixed at
room temperature with 3.7% formaldehyde in PBS for 20
min. Coverslips were again washed in PBS and incubated
with a blocking solution of PBS plus 10% NGS (Vector
Laboratories Inc.) and 0.1% (wt/vol) saponin for 20 min. A
1:100 dilution of primary antibodies was made in the block-
ing solution. AU5 (Babco, Berkeley, CA) was used as a
control primary MAb on pTW2-transfected cells as was
AU1 (Babco) on vector-transfected cells. Incubation with
the primary antibodies was carried out for 16–18 h at 4°C
in a humidified chamber. Coverslips were washed twice
with PBS and a goat anti-mouse or a goat anti-rabbit IgG
secondary-antibody (ICN Pharmaceuticals Inc., Costa
Mesa, CA) conjugated to trimethylrhodamine isothiocya-
nate, diluted at 1:50 in blocking buffer, was added. The
secondary-antibody incubation was carried out at room tem-
perature for 1 h in a humidified chamber. Following the
incubation, the coverslips were extensively washed with
PBS, allowed to air dry, and mounted on glass slides with
Fluoromount G (Fisher Scientific, Pittsburgh, PA). Cells
were examined and photographed with a Zeiss Axioskop
inverted fluorescence microscope.
Immunoprecipitation assays
Immunoprecipitation assays were performed on COS-1
cells at 48 h posttransfection. Cells were washed with PBS,
incubated with cysteine-methionine-free DMEM for 1.5 h,
and labeled for 4 h with 500 Ci of a commercial mixture
of 35S-labeled methionine (approximately 90%) and cys-
teine (10%) (Expre35S35S, NEN, Boston, MA) or a mixture
of 35S-labeled methionine (75%) and cysteine (25%) (Am-
ersham/Pharmacia Biotech Inc.) in 2 ml of DMEM at 37°C.
Cells were washed in PBS and extracted with 1 ml of a
modified RIPA buffer (20 mM Mops [morpholinepropane-
sulfonic acid], 150 mM NaCl, 1 mM EDTA, 1% [vol/vol]
Nonidet P-40, 1% [wt/vol] deoxycholate, and 0.1% [wt/vol]
sodium dodecyl sulfate, pH 7.0) containing protease inhib-
itors (0.1 mM TLCK [Na-p-tosyl-L-lysine chloromethyl
ketone], 0.1 mM TPCK [N-tosyl-L-phenylalanine chlorom-
ethyl ketone], and 0.5 mM PMSF [phenylmethylsulfonyl
fluoride] [Sigma, St. Louis, MO]). Extracts were vortexed
and centrifuged in Eppendorf microfuge tubes and pellets
discarded. Seventy-five microliters of a 1:1 suspension of
protein A-Sepharose CL-4B beads (Amersham/Pharmacia
Biotech Inc.) in PBS and the appropriate antibody (5 l
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AU1, 2 l anti-E5A [the anti-E5A polyclonal antibody was
raised in a rabbit against a synthetic peptide composed of
the last 20 amino acids of the BPV-1 E5A protein, Petti and
DiMaio, 1992]) 100 l W6/32 [ATCC, Rockville, MD], 10
l c-neu [Oncogene Science], or 10 l 06-131 [Upstate
Biotechnology]) were added to each supernatant. Following
a 1.5-h rotating incubation at 4°C, the Sepharose beads were
pelleted, washed four times in the lysis buffer, and resus-
pended in 80 l of sample buffer with or without 10%
(vol/vol) -mercaptoethanol. Samples were heated at 95°C
for 5 min and analyzed by SDS-PAGE. The precipitate from
one 10-cm plate was loaded into one lane unless otherwise
indicated. Gels were fixed in 30% methanol-10% glacial
acetic acid, treated with Enlightening (NEN), dried, and
exposed to Kodak XAR-5 film at 80°C.
Cell fractionation assay
Subconfluent COS-1 cells in 10 cm plates were trans-
fected with 10 g of pTW2 or pSVL as described above.
After 48 h, the cells were starved with cysteine-methionine-
free DMEM (Life Technologies) and labeled with 500 Ci
of a commercial mixture of 35S-labeled methionine-cysteine
for 4 h. Cells were washed with PBS and then with a cold
0.01% (wt/vol) Na-citrate solution. The cells were then
swollen with 2 ml of the hypotonic citrate solution at room
temperature for 15 min. The cell monolayer was removed
by scraping and was homogenized by vigorous pipetting
before centrifugation for 15 min to pellet the nuclei. The
pellet was washed and saved and the supernatant was fur-
ther centrifuged at 32,000 rpm for 1 h at 4°C and separated
into pellet (membrane) and supernatant (cytoplasm). All
fractions were brought to equal volumes with RIPA buffer
and vortexed prior to immunoprecipitation as described
previously.
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